

Amylin Pharmaceuticals, Inc. – Eli Lilly and Company Alliance Backgrounder

In 2002, Amylin Pharmaceuticals, Inc., (Amylin) and Eli Lilly and Company (Lilly) entered into a strategic agreement and formed a collaboration, which is referred to as the Amylin/Lilly Alliance. The Alliance is committed to developing treatment options for patients with diabetes.

Currently, the Alliance markets BYETTA[®] (exenatide) injection. Amylin and Lilly have also partnered with Alkermes, Inc. to develop an alternative delivery formulation for exenatide.

Amylin and Lilly co-promote BYETTA in the United States, equally sharing development and commercialization costs that generate utility predominantly in the United States. Outside of the United States, Lilly markets the product exclusively and is responsible for all development and commercialization costs. Additional development and commercialization costs that generate utility both in and outside the United States, including global manufacturing development expenses, are allocated 53 percent to Lilly and 47 percent to Amylin.

Amylin Pharmaceuticals, Inc.

Amylin Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving lives through the discovery, development, and commercialization of innovative medicines.

Amylin was founded in 1987 on the discovery of a hormone, amylin, produced by the same beta cells in the pancreas that make insulin. Since then, Amylin has built a strong foundation on research and development. Amylin's scientists are primarily focused on investigating the potential utility of new peptide hormone candidates. The company has amassed significant research and clinical expertise in metabolic medicine, including diabetes and obesity.

Eli Lilly and Company

Through a long-standing commitment to diabetes care, Lilly seeks to provide patients with breakthrough treatments that enable them to live longer, healthier, and fuller lives. Since 1923, Lilly has been an industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

###